Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig

Zambaux, M. F.; Faivre-Fiorina, Béatrice; Bonneaux, F.; Marchal, Sophie; Merlin, Jean‐Louis; Dellacherie, Édith; Labrude, Pierre; Vigneron, C.

doi:10.1016/s0142-9612(99)00233-1

Cited by 36 publications

(24 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, hydrophilic coating with PEG sterically stabilizes PLA or PLGA nanoparticles and reduces opsonization and phagocytosis in vitro 32 or ex vivo, 78 and uptake by neutrophilic granulocytes in vivo. 79 Compared with nonpegylated PLA nanoparticles, pegylated nanoparticle surfaces have lower negative potential values, due to the surface shielding by the PEG corona. 3,57,58 mPEG 2000 -PLA nanoparticles did not activate the complement 47 and the coagulation 77 systems in vitro and did not alter coagulation parameters in vivo.…”

Section: Pharmacokineticsmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

Section: Pharmacokineticsmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

show abstract

“…25 For example, after IV administration, PLA-PEG and PLGA-PEG nanoparticles remain in the systemic circulation for days, whereas PLA and PLGA nanoparticles are removed from blood within a few minutes. 26 Therefore, when conceiving original nanoparticles for targeting applications, it is not only necessary to adjust their morphology, generally looking for small particles, but also to prevent the opsonization phenomenon. Obviously, pegylation remains nowadays a very attractive strategy for achieving this goal.…”

Section: Introductionmentioning

confidence: 99%

Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats

Özcan¹,

Segura‐Sánchez²,

Bouchemal³

et al. 2010

IJN

View full text Add to dashboard Cite

Poly(γ-benzyl-L-glutamate) (PBLG) derivatives are synthetic polypeptides for preparing nanoparticles with well controlled surface properties. The aim of this paper was to investigate the biodistribution of pegylated PBLG in rats. For this purpose, nanoparticles were prepared by a nanoprecipitation method using mixtures of different PBLG derivates, including a pegylated derivate to avoid mononuclear phagocyte system uptake. The morphology, size distribution, and surface charge of the nanoparticles were investigated as a function of the amount of polymer employed for the preparation. Moderately polydispersed nanoparticles (polydispersity index less than 0.2) were obtained. Their size increased with polymer concentration. The zeta potential values were negative whatever the formulations. The availability of polyethylene glycol chains on the nanoparticles' surface was confirmed by measuring the decrease in bovine serum albumin adsorption. For in vivo distribution studies, pegylated and nonpegylated nanoparticles were prepared with polymer mixtures containing PBLG-fluorescein isothiocyanate and imaged by fluorescence microscopy to measure their accumulation in liver and spleen tissues of rats after intravenous administration. Injection of stealth formulations resulted in negligible fluorescence in liver and spleen compared with nonpegylated formulations, which suggests that these nanoparticles are promising candidates as a stealth-type long-circulating drug carrier system and could be useful for active targeting of drugs while reducing systemic side effects.

show abstract

“…Different nanoparticle surface coatings are used for different purposes: hydrophilic surfactants [41,68,[85][86][87] reduce nanoparticle absorption by reticuloendothelial system organs to alter biodistribution of the nanoparticle; poloxamers and poloxamines induce a steric repulsion effect, which minimises adhesion of nanoparticles to macrophage surfaces, consequently minimising phagocytic uptake [88]; surface PEGylation increases blood half-life of nanoparticles [49,89,90]; and polysorbate-80 improves BBB transport of nanoparticles [67,87,91,92]. Any coating used for CNS targeted nanoparticles must allow the interactions needed for BBB transport [88].…”

Section: Peptide Coated Nanoparticlesmentioning

confidence: 99%

The role of peptides in blood‐brain barrier nanotechnology

Teixidó

Giralt

2007

Journal of Peptide Science

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB) regulates the passage of molecules between the bloodstream and the brain. Overcoming the difficulty of delivery drugs to specific areas of the brain is a major challenge. The BBB exerts a neuroprotective function as it hinders the delivery of diagnostic and therapeutic agents to the brain. Here, we provide an overview of the way in which peptides and nanotechnology are being exploited in tandem to address this problem. Peptides can be used as specialised coatings able to transport nanoparticles with specific properties, such as targeting. The nanoparticle can also carry a peptide drug. Furthermore, peptides can be used in less conventional approaches such as all-peptide nanoparticles. In summary, the combined use of peptides and nanotechnology offers tremendous hope in the treatment of brain disorders.

show abstract

Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig

Cited by 36 publications

References 15 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats

The role of peptides in blood‐brain barrier nanotechnology

Contact Info

Product

Resources

About

Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig

Cited by 36 publications

References 15 publications

Drug transport to brain with targeted nanoparticles

Drug transport to brain with targeted nanoparticles

Pegylation of poly(&gamma;-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats

The role of peptides in blood‐brain barrier nanotechnology

Contact Info

Product

Resources

About

Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats